Objectives The authors sought to evaluate the safety and efficacy of atorvastatin
administered every other day in patients with hypercholesterolemia. Background Statins …

Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase introduced in clinical practice for the treatment of hypercholesterolemia. In …

Purpose The purpose of this study was to compare incidence rates of hospitalization
associated with rhabdomyolysis, myopathy, renal, or hepatic dysfunction, and of in‐hospital …

Statins are a standard of care in many clinical settings, especially for dyslipidemia
management, and are used for the primary and secondary prevention of cardiovascular …

Abstract The Fluvastatin Long-Term Extension Trial (FLUENT) evaluated the safety and
efficacy of fluvastatin over a period of 48 weeks. All 918 enrolled patients had severe …

Recent US guidelines expand the indications for high-intensity statin therapy, yet data on the
safety of attaining very low-density lipoprotein cholesterol (LDL-C) levels are scarce. Among …

The safety, tolerability, and efficacy of 20 mg daily doses of simvastatin and pravastatin were
compared in this double-blind, randomized trial of 210 patients with primary …

HMG-CoA reductase inhibitors (statins) are the mainstay in the pharmacologic management
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …

Introduction: Rosuvastatin is a highly efficacious statin approved for use throughout the
world. Rosuvastatin has been exhaustively evaluated in the setting of a broad variety of …

BACKGROUND:: Rosuvastatin is a new statin indicated to reduce elevated levels of total
cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides and to increase …